All In Biotech

Drug Trial Radar · NCT07790575

Autoimmune Cytopenia Elimination by Chimeric Antigen Receptor T-cell Therapy

A Phase 1, Open-Label, Single Center Study of AZD0120 (Also Known as GC012F), a Chimeric Antigen Receptor T Cell Therapy Targeting CD19 and B Cell Maturation Antigen (BCMA), in Subjects With Relapsed and Refractory Persistent Autoimmune Cytopenia

Last checked: Nov 19, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

16

Planned (sponsor's estimate)

Start

Sep 2026

Primary completion

Jul 2041

Study completion Jul 2041

Sponsor

Lead sponsor
Saurabh DahiyaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 1 study to evaluate the safety and tolerability of AZD0120 in patients with relapsed or refractory immune mediated cytopenia (primary chronic Immune Thrombocytopenia (ITP) or autoimmune hemolytic anemia (wAIHA)).

Conditions

  • Cytopenia

Interventions

  • AZD0120Drug

    One time administration on Day 0.

  • BendamustinDrug

    Participants will be given bendamustin for 2 days (study Day -5 and Day -4) followed by 3 days of rest.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse eventsTime frame: within 28 days after the CAR-T administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Stanford University

    Stanford, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.